StreetAlpha.app
Home › Stocks › PRME

Prime Medicine, Inc. (PRME)

Healthcare
$3.84
▼ −8.35%
LAST CLOSE · NOV 17

Prime Medicine is a Cambridge, Massachusetts biotechnology company developing gene editing medicines for genetic diseases. It last closed at $3.84 on Nov 17, down 8.35% on the day. In the past 30 days there were 2 dark pool prints totaling $283K, the largest $165K.

AI Auto Pilots
Is PRME in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$7.1M
+18.1% vs a year ago
Net income
−$176.4M
−2497.6% margin
EPS (diluted)
−$0.97
Free cash flow
−$158.5M
−2245.3% margin
Valuation
Market cap
$698.6M
181.9M shares
P/E
–
No P/E while losing money
Price to sales
98.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$54.9M
At Sep 30
Shareholder equity
$8.4M
Shares outstanding
181.9M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $3.0M$3.0MFY2024FY2025: $4.6M$4.6MFY2025

From PRME's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PRME in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 82.3% upside

Based on 1 analyst who set a price target on PRME in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $3.84.

Low $7.00Avg $7.00High $7.00
Blue marker: last close $3.84
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
Chardan CapitalMaintained
Sep 25Buy$7
Chardan CapitalMaintained
Aug 25Buy$7
BMO CapitalInitiated
Aug 19Buy$9
HC Wainwright & Co.Reiterated
Aug 10Buy$8
HC Wainwright & Co.Upgrade
Jun 29Buy$8
DateFirmActionRatingPrice target
Sep 25Chardan CapitalMaintainedBuy$7
Aug 25Chardan CapitalMaintainedBuy$7
Aug 19BMO CapitalInitiatedBuy$9
Aug 10HC Wainwright & Co.ReiteratedBuy$8
Jun 29HC Wainwright & Co.UpgradeBuy$8
Loading…

Technical Analysis

PRME · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 9% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the swing low (Nov 12) at $3.73, and the nearest resistance the swing high (Sep 4) at $3.86.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 12.3%/day
Key levels
$5.9152 week high+53.9%
$4.3120 day average+12.2%
$4.23Pivot R1+10.2%
$4.02Pivot+4.7%
$3.86Swing high (Sep 4)+0.5%
$3.84Last close
$3.73Swing low (Nov 12)−2.9%
$3.7150 day average−3.4%
$3.64Pivot S1−5.2%
$3.55100 day average−7.6%
$3.51200 day average−8.6%
$2.6752 week low−30.5%
Indicators
RSI (14)46.82Middle of its rangeNeutral
MACD0.09Below its signal lineBearish
Stochastic18.7Near the bottom of its rangeOversold
ADX (14)24.0Weak trend
Williams %R-95.0Oversold below −80, overbought above −20Oversold
CCI (20)-49.0Oversold below −100, overbought above 100Neutral
Rate of change−15.6%Change over 10 sessionsBearish
ATR (14)$0.47Typical daily range, 12.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for PRME

What happened before

See how PRME did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PRME usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PRME has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PRME in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$283K
Largest print
$165K
Loading…

PRME Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲93 buying vs 79 selling
  • ▲Held by funds +9.7 pts
  • ●Funds holding -1
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding186187−0.5%
In funds' top 1000–
Held by funds68.3%58.6%+9.7 pts
New / increased25 / 6822 / 62+10.7%
Reduced / sold out55 / 2466 / 24−12.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PRME institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRME is in one of them and how their past PRME trades turned out.

PRME in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PRME in an article yet. Here's the latest on the wider market.

About Prime Medicine

Prime Medicine is a biotechnology company based in Cambridge, Massachusetts. It develops gene editing medicines built on a technology called Prime Editing, which is designed to rewrite specific sections of DNA without cutting both strands of the double helix. The company's programs target inherited diseases, with early focus on conditions affecting the liver and lungs and on certain blood disorders. Its medicines are intended for patients with these genetic conditions and the doctors who treat them.

Headquarters
Cambridge, MA